249 related articles for article (PubMed ID: 24617286)
1. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients.
Hvid-Jensen F; Pedersen L; Funch-Jensen P; Drewes AM
Aliment Pharmacol Ther; 2014 May; 39(9):984-91. PubMed ID: 24617286
[TBL] [Abstract][Full Text] [Related]
2. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
3. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis.
Singh S; Garg SK; Singh PP; Iyer PG; El-Serag HB
Gut; 2014 Aug; 63(8):1229-37. PubMed ID: 24221456
[TBL] [Abstract][Full Text] [Related]
4. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
5. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Med J Aust; 2004 Apr; 180(8):387-91. PubMed ID: 15089728
[TBL] [Abstract][Full Text] [Related]
6. Letter: proton pump inhibitor usage still seems to reduce the risk of high-grade dysplasia and/or oesophageal adenocarcinoma in Barrett's oesophagus.
Aydin Y; Akin H
Aliment Pharmacol Ther; 2014 Oct; 40(7):859-60. PubMed ID: 25185738
[No Abstract] [Full Text] [Related]
7. Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus?
Akın H; Aydın Y
Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S31-S32. PubMed ID: 29199164
[TBL] [Abstract][Full Text] [Related]
8. Letter: proton pump inhibitor usage still seems to reduce the risk of high-grade dysplasia and/or oesophageal adenocarcinoma in Barrett's oesophagus--authors' reply.
Hvid-Jensen F; Drewes AM; Funch-Jensen P
Aliment Pharmacol Ther; 2014 Oct; 40(7):860-1. PubMed ID: 25185739
[No Abstract] [Full Text] [Related]
9. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
[TBL] [Abstract][Full Text] [Related]
10. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
Dunbar KB; Souza RF; Spechler SJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
[TBL] [Abstract][Full Text] [Related]
12. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.
Chen Y; Sun C; Wu Y; Chen X; Kailas S; Karadsheh Z; Li G; Guo Z; Yang H; Hu L; Zhou Q
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2681-2691. PubMed ID: 33575855
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Steyerberg EW; Biermann K; Valkhoff VE; Kuipers EJ; Bruno MJ;
Clin Gastroenterol Hepatol; 2013 Apr; 11(4):382-8. PubMed ID: 23200977
[TBL] [Abstract][Full Text] [Related]
14. [Endoscopic treatment of Barrett's oesophagus].
Boyer J
Ann Chir; 2006 Jan; 131(1):7-11. PubMed ID: 16376846
[TBL] [Abstract][Full Text] [Related]
15. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
Tsibouris P; Hendrickse MT; Isaacs PE
Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
[TBL] [Abstract][Full Text] [Related]
16. Barrett's oesophagus: frequency and prediction of dysplasia and cancer.
Falk GW
Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):125-38. PubMed ID: 25743461
[TBL] [Abstract][Full Text] [Related]
17. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and prevention of oesophageal adenocarcinoma.
Ness-Jensen E
Scand J Gastroenterol; 2022 Aug; 57(8):891-895. PubMed ID: 35234549
[TBL] [Abstract][Full Text] [Related]
19. Barrett's oesophagus: an audit of surveillance over a 17-year period.
Gladman L; Chapman W; Iqbal TH; Gearty JC; Cooper BT
Eur J Gastroenterol Hepatol; 2006 Mar; 18(3):271-6. PubMed ID: 16462540
[TBL] [Abstract][Full Text] [Related]
20. Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett's esophagus: a cohort study.
Thota PN; Hajifathalian K; Benjamin T; Runkana A; Lopez R; Sanaka MR
J Dig Dis; 2017 Mar; 18(3):143-150. PubMed ID: 28188977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]